An addition to pharmacological correction of carbohydrate and lipid metabolism in patients with metabolic syndrome

Obesity is the cause of many diseases, as well as psycho-emotional, social and economic problems. Factors predisposing to the development of metabolic syndrome are genetic predisposition, advanced age, postmenopausal status in women, behavioral factors (a sedentary lifestyle, the predominance of fatty foods in the diet), and low socioeconomic status. Metabolic syndrome is characterized by an increase in the mass of visceral fat, a decrease in the sensitivity of peripheral tissues to insulin and hyperinsulinemia, which cause the development of disorders of carbohydrate, lipid, purine metabolism and arterial hypertension. The presence of metabolic syndrome leads to an increased risk of developing type 2 diabetes and cardiovascular disease. The risk of mortality associated with cardiovascular disease is also higher in those diagnosed with this syndrome. Fiber supplements can be a convenient and cost-effective alternative to increase fiber content in the diet without the need for other major dietary modifications. Psyllium has been extensively researched as it is found in many popular over-the-counter laxatives around the world. Numerous studies point to improved glycemic and HbA_1c control in people with type 1 or type 2 diabetes who consumed more dietary fiber. According to the Управление по надзору за качеством пищевых продуктов и лекарственных средств Food and Drugs Administration of the United States, consumption of 1.78 g of psyllium per serving (4 servings per day) improves lipid levels, reduces cardiovascular risk factors. Studies have not shown any improvement in BP or vascular function in overweight and obese individuals with psyllium fiber supplementation during the 12 weeks of intervention. A 2016 randomized clinical trial showed statistically significant reductions in weight, body mass index, and waist and hip circumference in patients with type 2 diabetes. In the Russian Federation, psyllium is also presented in the form of the drug.

1. World Health Organisation. World Health Statistics 2014. Geneva, Switzerland: WHO; 2014.

2. Wilborn C., Beckham J., Campbell B., et al. Obesity: prevalence, theories, medical consequences, management, and research directions // J Int Soc Sports Nutr. 2005; 2 (2): 4-31. Published 2005 Dec 9. DOI: 10.1186/1550-2783-2-2-4.

3. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Belgium: IDF; 2006.

4. International Diabetes Federation. Criteria of metabolic syndrome in children and adolescents. Belgium: IDF; 2015.

5. Zhu L., Spence C., Yang J. W., Ma G. X. The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016 // J Clin Med. 2020; 9 (12): 3871. Published 2020 Nov 28. DOI: 10.3390/jcm9123871.

6. Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.

7. Recommendations for the management of patients with metabolic syndrome. Ministerstvo zdravookhraneniya Rossiyskoi Federatsii, Moskva, 2013 g.

8. Bovolini A., Garcia J., Andrade M. A., Duarte J. A. Metabolic Syndrome Pathophysiology and Predisposing Factors // Int J Sports Med. 2021; 42 (3): 199-214. DOI: 10.1055/a-1263-0898.

9. Riccioni G., Sblendorio V., Gemello E., Di Bello B., Scotti L., Cusenza S., et al. Dietary fibers and cardiometabolic diseases // International Journal of Molecular Sciences. 2012; 13: 1524-1540.

10. Hartley L., May M. D., Loveman E., Colquitt J. L., K. R. Dietary fibre for the primary prevention of cardiovascular disease // Cochrane Database of Systematic Reviews. 2016; 1.

11. McKeown N. M., Fahey G. C. Jr., Slavin J., van der Kamp J. W. Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations? // BMJ. 2022; 378: e054370. Published 2022 Jul 20. DOI: 10.1136/bmj-2020-054370.

12. Australian Bureau of Statistics. Australian Health Survey: Consumption of food groups from the Australian Dietary Guidelines. Canberra: Commonwealth of Australia; 2016.

13. Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.

14. Jane M., McKay J., Pal S. Effects of daily consumption of psyllium, oat bran and polyGlycopleX on obesity-related disease risk factors: A critical review // Nutrition. 2019; 57: 84-91. DOI: 10.1016/j.nut.2018.05.036.

15. Phillips K. M., McGinty R. C., Couture G., Pehrsson P. R., McKillop K., Fukagawa N. K. Dietary fiber, starch, and sugars in bananas at different stages of ripeness in the retail market // PLoS One. 2021; 16 (7): e0253366. Published 2021 Jul 8. DOI: 10.1371/journal.pone.0253366.

16. Williams P. G. The benefits of breakfast cereal consumption: a systematic review of the evidence base // Adv Nutr. 2014; 5 (5): 636S-673S. Published 2014 Sep 15. DOI: 10.3945/an.114.006247.

17. Sec. 101.81 Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD) Archived 2019-05-23 at the Wayback Machine U.S. Food and Drug Administration, Code of Federal Regulations Title 21.

18. Qualified Health Claim for Diabetes Archived 2017-05-08 at the Wayback Machine US Food and Drug Administration (June 24, 2014).

19. McRorie J. W. Psyllium Is Not Fermented in the Human Gut. Neurogastroenterol // Motil. 2015; 27: 1681-1682. DOI: 10.1111/nmo.12649.

20. Silva F. M., Kramer C. K., de Almeida J. C., Steemburgo T., Gross J. L., Azevedo M. J. Fiber Intake and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials // Nutr. Rev. 2013; 71: 790-801. DOI: 10.1111/nure.12076.

21. McRae M. P. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-Analyses // J. Chiropr. Med. 2018; 17: 44-53. DOI: 10.1016/j.jcm.2017.11.002.

22. Sandberg J. C., Björck I. M. E., Nilsson A. C. Effects of Whole Grain Rye, with and without Resistant Starch Type 2 Supplementation, on Glucose Tolerance, Gut Hormones, Inflammation and Appetite Regulation in an 11-14.5 Hour Perspective; a Randomized Controlled Study in Healthy Subjects // Nutr. J. 2017; 16: 25. DOI: 10.1186/s12937-017-0246-5.

23. Thompson S. V., Hannon B. A., An R., Holscher H. D. Effects of Isolated Soluble Fiber Supplementation on Body Weight, Glycemia, and Insulinemia in Adults with Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials // Am. J. Clin. Nutr. 2017; 106: 1514-1528. DOI: 10.3945/ajcn.117.163246.

24. Pal S., Khossousi A., Binns C., Dhaliwal S., Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals // Br J Nutr. 2011; 105 (1): 90-100. DOI: 10.1017/S0007114510003132.

25. Pal S., Radavelli-Bagatini S. Effects of psyllium on metabolic syndrome risk factors // Obes Rev. 2012; 13 (11): 1034-1047. DOI: 10.1111/j.1467-789X.2012.01020.x.

26. Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. Published 2016 Oct 12. DOI: 10.1186/s12937-016-0207-4.

27. Khossousi A., Binns C. W., Dhaliwal S. S., Pal S. The acute effects of psyllium on postprandial lipaemia and thermogenesis in overweight and obese men // Br J Nutr. 2008; 99 (5): 1068-1075. DOI: 10.1017/S0007114507864804.

28. FDA. Control of health claims in foods // Lancet. 1998; 351: 609. DOI: 10.1016/S0140-6736(98)21009-9.

29. Jenkins D. J., Kendall C. W., Vuksan V., et al. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial // Am J Clin Nutr. 2002; 75 (5): 834-839. DOI: 10.1093/ajcn/75.5.834.

30. Sierra M., García J. J., Fernández N., Diez M. J., Calle A. P. Therapeutic effects of psyllium in type 2 diabetic patients // Eur J Clin Nutr. 2002; 56 (9): 830-842. DOI: 10.1038/sj.ejcn.1601398.

31. Anderson J. W., Zettwoch N., Feldman T., Tietyen-Clark J., Oeltgen P., Bishop C. W. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men // Arch Intern Med. 1988; 148 (2): 292-296.

32. Jovanovski E., Yashpal S., Komishon A., et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials // Am J Clin Nutr. 2018; 108 (5): 922-932. DOI: 10.1093/ajcn/nqy115.

33. Pal S., Khossousi A., Binns C., Dhaliwal S., Radavelli-Bagatini S. The effects of 12-week psyllium fibre supplementation or healthy diet on blood pressure and arterial stiffness in overweight and obese individuals // Br J Nutr. 2012; 107 (5): 725-734. DOI: 10.1017/S0007114511003497.

34. Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. DOI: 10.1186/s12937-016-0207-4. PMID: 27733151; PMCID: PMC5062871.

35. Alemán A. M., Quirce S., Bombín C., Sastre J. Asma relacionada con la inhalación de Plantago ovata [Asthma related to inhalation of Plantago ovata] // Med Clin (Barc). 2001; 116 (1): 20-22.

36. Pal S., McKay J., Ho S., Jane M., Gahler R. J., Wood S. Micronutrient status of individuals with overweight and obesity following 3 months' supplementation with PolyGlycopleX (PGX®) or psyllium: a randomized controlled trial // BMC Nutr. 2022; 8 (1): 42. Published 2022 May 3. DOI: 10.1186/s40795-022-00534-7.

37. Мукофальк® в клинической практике, DR. FALK PHARMA GmbH, 2014. [Mucofalk® in clinical practice, DR. FALK PHARMA GmbH, 2014]

38. Huwiler V. V., Schönenberger K. A., Segesser von Brunegg A., et al. Prolonged Isolated Soluble Dietary Fibre Supplementation in Overweight and Obese Patients: A Systematic Review with Meta-Analysis of Randomised Controlled Trials // Nutrients. 2022; 14 (13): 2627. Published 2022 Jun 24. DOI: 10.3390/nu14132627.

39. Pollet A., van Craeyveld V., van de Wiele T., Verstraete W., Delcour J. A., Courtin C. M. In vitro fermentation of arabinoxylan oligosaccharides and low molecular mass arabinoxylans with different structural properties from wheat (Triticum aestivum L.) bran and psyllium (Plantago ovata Forsk) seed husk // J Agric Food Chem. 2012; 60 (4): 946-954. DOI: 10.1021/jf203820j